On April 28, 2014, details were submitted to clinicaltrials.gov of the DREAM study (Dry Eye Assessment and Management Study).

There is a hypothesis that omega-3 supplementation is an effective treatment for Dry Eye Disease (DED). The objective of the DREAM study is to evaluate that hypothesis by testing the effectiveness and safety of omega-3 fatty acid supplementation in relieving symptoms of moderate to severe dry eye disease in a randomized, double blind clinical trial.

The primary outcome measure of the trial will be the mean of change from baseline in OSDI score at 6 and 12 months (note: for lay readers, OSDI stands for Ocular Surface Disease Index and is a method of using various symptoms to determine the extent of dry eye disease).

Recruitment is expected to begin in June 2014 at sites throughout the country.

Click here ^[1] for further details about the trial, including criteria for participation.